Symbiotec Pharmalab, a science-driven pharmaceutical and biotechnology company, today announced a 10-year, take-or-pay contract development and manufacturing agreement with a European alternative protein innovator. The agreement reserves dedicated capacity for the partner at Symbiotec's Ujjain campus for the full term.
Under the agreement, production will be based at Symbiotec's biomanufacturing campus in Ujjain, which features four 100 kilolitre (kL) fermenters, modular downstream processing, and integrated quality assurance and quality control capabilities. Production begins at the existing facility, with a new dedicated plant of several hundred thousand litres of fermentation capacity to follow, and contracted expansion options reserved for the partner that take the programme into the millions of litres.
Precision fermentation uses engineered microorganisms to produce proteins traditionally derived from animals. These ingredients must meet high-quality standards and be produced at a cost that allows wide adoption, two demands that usually pull against each other. Symbiotec brings both: the quality systems of a pharmaceutical manufacturer, and a long record of building and running its own fermentation plants at scale.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."